Christopher Kimball

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised Harvey, a domain-specific artificial intelligence platform for legal and professional services, on its $300 million Series E at a $5 billion valuation.

Cooley advised Mach Industries, a new industrial base for the unmanned era of American defense, on its $100 million Series B financing.

Cooley advised Runwise, a smart operating system for buildings, on its $55 million Series B financing round, bringing the company’s total funding to $79 million.

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.